Zacks Investment Research upgraded shares of Vision-Sciences Inc. (NASDAQ:CGNT) from a sell rating to a hold rating in a research report sent to investors on Tuesday.

According to Zacks, “Cogentix Medical, Inc. is a medical device company which designs, develops, manufactures and markets proprietary technologies serving the urology market. The company’s primary product consists of Urgent(R) PC Neuromodulation System and EndoSheath System. It operates primarily in Orangeburg, New York, The Netherlands and the United Kingdom. Cogentix Medical, Inc., formerly known as Vision-Sciences Inc., is headquartered in Orangeburg, New York. “

Separately, Roth Capital upgraded shares of Vision-Sciences from a neutral rating to a buy rating in a report on Wednesday, September 7th.

Shares of Vision-Sciences (NASDAQ:CGNT) traded down 1.8101% during mid-day trading on Tuesday, reaching $1.7576. 30,486 shares of the company traded hands. The firm’s market capitalization is $45.95 million. Vision-Sciences has a 52 week low of $0.71 and a 52 week high of $1.99. The firm has a 50-day moving average price of $1.50 and a 200 day moving average price of $1.15.

Vision-Sciences (NASDAQ:CGNT) last issued its earnings results on Tuesday, August 2nd. The medical device company reported ($0.10) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.01 by $0.11. Vision-Sciences had a negative return on equity of 27.43% and a negative net margin of 13.99%. On average, analysts anticipate that Vision-Sciences will post ($0.21) earnings per share for the current year.

An institutional investor recently raised its position in Vision-Sciences stock. Amici Capital LLC raised its position in Vision-Sciences Inc. (NASDAQ:CGNT) by 14.6% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,415,589 shares of the medical device company’s stock after buying an additional 180,689 shares during the period. Amici Capital LLC owned 5.58% of Vision-Sciences worth $1,557,000 at the end of the most recent quarter. 30.43% of the stock is owned by hedge funds and other institutional investors.

Vision-Sciences Company Profile

Cogentix Medical, Inc, formerly Vision-Sciences, Inc, is a medical device company. The Company designs, develops, manufactures and markets products for endoscopy with its product lines featuring a visualization system and sterile disposable microbial barrier, EndoSheath technology. The Company produces and markets Endoscopes, such as cystoscopes, ureteroscopes, laryngoscopes, otoscopes, sinuscopes, trans-nasal esophagoscopy (TNE) and bronchoscopes for medical use and borescopes for industrial use, and digital processing units (DPU).

5 Day Chart for NASDAQ:CGNT

Receive News & Stock Ratings for Vision-Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vision-Sciences Inc. and related stocks with our FREE daily email newsletter.